Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Edition
European
US
General Healthcare
Filter
Journals
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Metformin: Hidden Brain Pathway to Lower Blood Sugar Revealed
March 2026
Scientists have discovered a previously unknown neural pathway behind the antidiabetic effects of metformin, a standard first-line treatment for Type 2 diabetes.
Read more
23 Jul 2015
Gilead Announces Phase 3 Results from the First Study to Evaluate Switching from TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF)
VANCOUVER, July 21, 2015 – Gilead Sciences, Inc. (NASDAQ: GILD) today announced detailed 48 week data from an open-label Phase 3 study (Study 109)…
2 Jul 2015
SENRI Trial Opens Window to Evaluate NK1 Antagonists for Emesis Prevention in Oxaliplatin Chemotherapy
BARCELONA-LUGANO, 1 July 2015 – The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin…
25 Jun 2015
Biosense Webster Launches CARTO® 3 System CONFIDENSE™ Module for Optimized High-Density Mapping During Catheter Ablation Procedures
Diamond Bar, Calif., June 18, 2015 – Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced today…
17 Jun 2015
New ICS Impulse Transforms Balance Assessment
Taastrup, Denmark | April, 2015 – GN Otometrics, the leading global manufacturer of hearing and balance instrumentation, announced today the…
15 Jun 2015
Visualising Calcified Coronary Arteries May Be Wake-Up Call to Change Lifestyle
Dubrovnik, Croatia – 15 June 2015: Looking at images of their own calcified coronary arteries may be a wake-up call for patients with newly diagnosed…
26 May 2015
New Data on BIOTRONIK Orsiro Hybrid Drug-Eluting Stent Demonstrates Enhanced Safety and Three-Times Reduced Risk of Stent Thrombosis
BUELACH, Switzerland, May 26, 2015—BIOTRONIK, a leading manufacturer of cardio- and endovascular medical technology, announced that positive new…
18 May 2015
Exercise, However Modest, Found Progressively Beneficial to the Elderly
15 May 2015, Lisbon, Portugal. Even exercise of short duration and low intensity has life expectancy benefits for the elderly. Such conclusions have been…
14 May 2015
Success of Colorectal Cancer Screening Programmes May Be Pushing Endoscopy Services to Breaking Point
(May 14, 2015) Successful implementation of pan-European colorectal cancer (CRC) screening programmes may be pushing endoscopy services to the limit…
Loading posts...
« Previous
1
…
52
53
54
55
56
…
58
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View